ArticleAnnals of medicine2025
The value of plasma presepsin as a diagnostic and prognostic biomarker for febrile neutropenia in children.
Article in Annals of medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- CD48 as a Novel Early Biomarker Complementing Procalcitonin and Lactate for Predicting Bacteremia in Pediatric Febrile Neutropenia: A Prospective Cohort Study.Mediterranean journal of hematology and infectious diseases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFebrile neutropenia (FN) is a prevalent infectious complication in paediatric cancer patients undergoing anticancer treatment. Presepsin is a reliable biomarker for sepsis; however, its clinical value in the context of paediatric FN remains unclear. This study aimed to evaluate the efficacy of presepsin in the entire course of paediatric patients with FN.
methodsIn this prospective study, 108 paediatric patients with haematological tumours complicated with neutropenia were recruited, of whom 23 had febrile neutropenia. Blood samples were collected daily, and four inflammation biomarkers, presepsin, procalcitonin (PCT), interleukin-6 (IL-6) and C-reactive protein (CRP), were analyzed. Clinical and laboratory parameters were collected, and the diagnostic and prognostic value of biomarkers for FN was assessed.
resultsThe concentrations of presepsin, PCT, IL-6 and CRP were prospectively measured in 57 FN episodes in 23 cases of malignant haematological diseases in children. The concentrations of presepsin, PCT and CRP were significantly elevated 72 h before onset compared to those in the control group. Only the concentration of presepsin at FN onset was significantly higher than 72 h before FN onset. The area under the curve (AUC) of presepsin, PCT, IL-6 and CRP for FN diagnosis 24 h before FN onset were 0.9118, 0.8214, 0.9052 and 0.8286, respectively. For prognosis, the levels of presepsin were consistently and significantly higher at every time point in patients with unfavourable outcomes than in those with favourable outcomes.
conclusionPresepsin demonstrated the best performance in both the early diagnosis and prognosis assessment of FN, indicating that it is a reliable biomarker for managing the entire FN process. Close monitoring of presepsin may enable earlier intervention for FN, reducing the occurrence of adverse events caused by infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.